SCHEMBL6322381

SCHEMBL6322381

COc1ccc(S(=O)(=O)N(Cc2ccccc2)C(C)O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 4/20 0.64
KEAP1 Q14145 2/20 0.62
NFE2L2 Q16236 1/20 0.62
BMP1 P13497 3/20 0.61
PTGES O14684 1/20 0.58
TAS2R8 Q9NYW2 1/20 0.58
CXCR3 P49682 1/20 0.58
NR3C1 P04150 1/20 0.56
PGR P06401 1/20 0.56
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
KCNA5 P22460 1/20 0.56
MMP2 P08253 2/20 0.55
MMP9 P14780 2/20 0.55
MMP8 P22894 1/20 0.55
CNR1 P21554 1/20 0.54
CNR2 P34972 1/20 0.54
BACE1 P56817 1/20 0.54
HTT P42858 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7343979 0.87 KEAP1 (0.81) TAS2R14KEAP1NFE2L2BMP1PTGES
SCHEMBL6325795 0.87 TAS2R14 (0.61) TAS2R14KEAP1NFE2L2BMP1PTGES
SCHEMBL6324153 0.87 TAS2R14 (0.61) TAS2R14KEAP1NFE2L2BMP1PTGES
SCHEMBL7348080 0.87 KEAP1 (0.81) TAS2R14KEAP1NFE2L2BMP1PTGES
SCHEMBL6324157 0.87 TAS2R14 (0.61) TAS2R14KEAP1NFE2L2BMP1PTGES
SCHEMBL6325058 0.86 TAS2R14 (0.61) TAS2R14KEAP1NFE2L2BMP1PTGES
SCHEMBL6322372 0.85 MMP9 (0.62) TAS2R14BMP1MMP2MMP9MMP8
SCHEMBL7091056 0.85 MMP2 (0.76) TAS2R14KEAP1NFE2L2BMP1PTGES
SCHEMBL7341408 0.85 KEAP1 (0.67) TAS2R14KEAP1NFE2L2BMP1PTGES
SCHEMBL6321710 0.85 TAS2R14 (0.59) TAS2R14KEAP1NFE2L2BMP1PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed
EP-0939629-A4 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO CO (US) 2002-07-17 EP disclosed
EP-0939629-A1 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO COMPANY (US) 1999-09-08 EP disclosed
WO-1998003166-A1 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO COMPANY (US) 1998-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 TAS2R14 1996/4885KEAP1 1604/4885NFE2L2 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.